美国痛风患者启动降尿酸治疗前进行HLA-B*5801筛查的成本效益分析
该研究评估了美国不同种族/族裔痛风患者在开始别嘌醇治疗前普遍进行HLA-B*5801筛查的成本效益。结果显示,与不筛查相比,普遍筛查对所有种族/族裔均增加成本并提高效果,但仅在非洲裔美国人和亚洲人中具有成本效益,在白人和西班牙裔中则不具有成本效益。
要点
- HLA-B*5801筛查在亚洲人和非洲裔美国人中具有成本效益。
- 在白人和西班牙裔中,筛查的ICER超过美国支付意愿阈值。
- 若SJS/TEN风险减半,筛查对所有种族均不具成本效益。
核心结论
- 在美国,痛风患者开始别嘌醇治疗前进行HLA-B*5801筛查对亚洲人和非洲裔美国人具有成本效益,但对白人和西班牙裔不具有成本效益。
研究设计与样本
- 基于美国特定数据的成本效益分析,比较普遍筛查HLA-B*5801与不筛查,按种族/族裔建模,评估终身成本、QALYs和ICERs。
主要发现
- 与不筛查相比,普遍筛查对所有种族/族裔均成本更高且更有效。
- ICERs随HLA-B*5801患病率变化:非洲裔美国人$83,450,亚洲人$64,190,白人和西班牙裔$183,720。
- 以美国支付意愿阈值$109,000/QALY判断,筛查仅对非洲裔美国人和亚洲人具有成本效益。
- 敏感性分析结果稳健,但将SJS/TEN风险降低一半会使筛查对所有种族/族裔均不具成本效益。
关键数值与推荐
- 建模的SJS/TEN风险:白人和西班牙裔1/3846,非洲裔美国人1/735,亚洲人1/336。
- 建模的HLA-B*5801患病率:白人和西班牙裔0.7%,非洲裔美国人3.8%,亚洲人7.4%。
- 美国支付意愿阈值为$109,000/QALY。
临床怎么用
- 在开始别嘌醇治疗前,可考虑对亚洲人和非洲裔美国人进行HLA-B*5801筛查以指导初始降尿酸治疗。
- 对白人和西班牙裔患者,普遍筛查可能不具有成本效益。
局限性
- 结果基于建模和假设,可能受其他预测措施降低AHS风险的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Positive HLA-B*5801 carriers are at greater risk of experiencing rare but severe allopurinol hypersensitivity syndrome (AHS) [i.e., Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)]; however, HLA-B*5801 prevalence and AHS risk vary by race/ethnicity. We evaluated the cost-effectiveness of HLA-B*5801 testing according to race/ethnicity in the United States. METHODS: We determined the cost-effectiveness of universal testing for HLA-B*5801 compared to no testing prior to the initiation of allopurinol per US major race/ethnicity groups. Using US-specific data, SJS/TEN risks and HLA-B*5801 prevalences were modeled per race/ethnicity (i.e., 1/3846 and 0.7% among Caucasians and Hispanics, 1/735 and 3.8% among African Americans, and 1/336 and 7.4% among Asians, respectively). Those who tested positive for HLA-B*5801 received febuxostat. Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were estimated over a lifetime. RESULTS: Compared to no testing, universal testing for HLA-B*5801 costs more and was more effective for all races/ethnicities. The ICERs varied substantially across racial/ethnic groups, following their HLA-B*5801 prevalences. HLA-B*5801 testing was cost-effective for African Americans (ICER $83,450) and Asians (ICER $64,190), but not for Caucasians or Hispanics (ICER $183,720), using accepted US willingness-to-pay threshold ($109,000/QALY). Results were robust in sensitivity analyses, except that reducing the risk of SJS/TEN by a half made testing not cost-effective for all races/ethnicities. CONCLUSION: Testing for HLA-B*5801 prior to allopurinol initiation is cost-effective for Asians and African Americans, but not for Caucasians or Hispanics in the United States. Reducing AHS risk by other predictive measures could make HLA-B*5801 testing not cost-effective even among Asians and Blacks.
引用
- Jutkowitz E, Dubreuil M, Lu N, et al. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2016. PMID: 27916277. doi:10.1016/j.semarthrit.2016.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。